Major Estimate Revision • Jul 05
Consensus EPS estimates increase by 14% The consensus outlook for fiscal year 2027 has been updated. 2027 EPS estimate increased from CHF8.52 to CHF9.74. Revenue forecast unchanged at CHF520.6m. Net income forecast to grow 4.1% next year vs 13% growth forecast for Pharmaceuticals industry in Switzerland. Consensus price target of CHF387 unchanged from last update. Share price was steady at CHF274 over the past week. New Risk • Jun 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swiss stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Announcement • Jun 01
Dottikon ES Holding AG, Annual General Meeting, Jul 02, 2026 Dottikon ES Holding AG, Annual General Meeting, Jul 02, 2026, at 16:00 W. Europe Standard Time. Reported Earnings • Jun 01
Full year 2026 earnings: EPS and revenues miss analyst expectations Full year 2026 results: EPS: CHF7.49 (down from CHF7.64 in FY 2025). Revenue: CHF439.9m (up 12% from FY 2025). Net income: CHF103.6m (down 1.9% from FY 2025). Profit margin: 24% (down from 27% in FY 2025). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.7%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 7% per year. Announcement • May 31
Dottikon ES Holding AG to Report Fiscal Year 2027 Results on May 31, 2027 Dottikon ES Holding AG announced that they will report fiscal year 2027 results on May 31, 2027 New Risk • May 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swiss stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Jan 31
Büchi AG agreed to acquire 33.70% stake in SYSTAG, System Technik AG from Dottikon ES Holding AG (SWX:DESN). Büchi AG agreed to acquire 33.70% stake in SYSTAG, System Technik AG from Dottikon ES Holding AG (SWX:DESN) on January 30, 2026. As a first step, Büchiglas will acquire a 15.6 percent stake in Systag, Dottikon announced on Friday. In a second step, Büchiglas will then increase this strategic investment to a total of 33.7%. This will also involve Büchiglas acquiring shares directly held by Dottikon. Upon completion, Dottikon itself will retain a strategic stake of 33.4% in Systag after the completion of these two transactions.
The expected completion of the transaction is by the end of 2027. Price Target Changed • Dec 04
Price target increased by 31% to CHF460 Up from CHF350, the current price target is provided by 1 analyst. New target price is 31% above last closing price of CHF350. Stock is up 47% over the past year. The company is forecast to post earnings per share of CHF9.23 for next year compared to CHF7.64 last year. Announcement • Dec 04
Dottikon ES Holding AG to Report Fiscal Year 2026 Results on May 29, 2026 Dottikon ES Holding AG announced that they will report fiscal year 2026 results on May 29, 2026 Announcement • Nov 29
Dottikon ES Holding AG to Report First Half, 2027 Results on Nov 27, 2026 Dottikon ES Holding AG announced that they will report first half, 2027 results on Nov 27, 2026 Reported Earnings • May 30
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: EPS: CHF7.64 (up from CHF5.84 in FY 2024). Revenue: CHF394.5m (up 19% from FY 2024). Net income: CHF105.6m (up 31% from FY 2024). Profit margin: 27% (up from 24% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 52%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. New Risk • May 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swiss stocks, typically moving 4.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (4.3% average weekly change). Valuation Update With 7 Day Price Move • May 28
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CHF261, the stock trades at a trailing P/E ratio of 47.8x. Average trailing P/E is 25x in the Pharmaceuticals industry in Switzerland. Total returns to shareholders of 2.8% over the past three years. Reported Earnings • Dec 01
First half 2025 earnings released: EPS: CHF2.33 (vs CHF2.71 in 1H 2024) First half 2025 results: EPS: CHF2.33 (down from CHF2.71 in 1H 2024). Revenue: CHF161.3m (up 2.8% from 1H 2024). Net income: CHF32.3m (down 14% from 1H 2024). Profit margin: 20% (down from 24% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Nov 28
Dottikon ES Holding AG to Report First Half, 2025 Results on Nov 29, 2024 Dottikon ES Holding AG announced that they will report first half, 2025 results on Nov 29, 2024 Reported Earnings • Jun 01
Full year 2023 earnings released: EPS: CHF6.35 (vs CHF4.29 in FY 2022) Full year 2023 results: EPS: CHF6.35 (up from CHF4.29 in FY 2022). Revenue: CHF328.7m (up 31% from FY 2022). Net income: CHF87.7m (up 48% from FY 2022). Profit margin: 27% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.9% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Buying Opportunity • Dec 19
Now 20% undervalued Over the last 90 days, the stock is up 18%. The fair value is estimated to be CHF318, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 25%. Reported Earnings • Dec 01
First half 2023 earnings released: EPS: CHF2.82 (vs CHF1.73 in 1H 2022) First half 2023 results: EPS: CHF2.82 (up from CHF1.73 in 1H 2022). Revenue: CHF138.2m (up 36% from 1H 2022). Net income: CHF38.9m (up 63% from 1H 2022). Profit margin: 28% (up from 24% in 1H 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 30
Dottikon Es Holding AG to Report First Half, 2024 Results on Nov 28, 2023 Dottikon Es Holding AG announced that they will report first half, 2024 results on Nov 28, 2023 Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Bernhard Urwyler was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Oct 26
Investor sentiment improved over the past week After last week's 17% share price gain to CHF238, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 27x in the Chemicals industry in Switzerland. Total returns to shareholders of 426% over the past three years. Reported Earnings • Jun 01
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: EPS: CHF4.29 (up from CHF4.15 in FY 2021). Revenue: CHF259.9m (up 19% from FY 2021). Net income: CHF59.3m (up 13% from FY 2021). Profit margin: 23% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 14%, compared to a 10% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 09
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CHF243, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 34x in the Chemicals industry in Switzerland. Total returns to shareholders of 435% over the past three years. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Bernhard Urwyler was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment improved over the past week After last week's 18% share price gain to CHF252, the stock trades at a trailing P/E ratio of 63x. Average forward P/E is 32x in the Chemicals industry in Switzerland. Total returns to shareholders of 474% over the past three years. Reported Earnings • Nov 30
First half 2022 earnings: EPS in line with analyst expectations despite revenue beat First half 2022 results: EPS: CHF1.73 (up from CHF1.69 in 1H 2021). Revenue: CHF101.8m (up 11% from 1H 2021). Net income: CHF23.9m (up 13% from 1H 2021). Profit margin: 24% (in line with 1H 2021). Revenue exceeded analyst estimates by 5.4%. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 84% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment improved over the past week After last week's 18% share price gain to CHF250, the stock trades at a trailing P/E ratio of 60.2x. Average forward P/E is 40x in the Chemicals industry in Switzerland. Total returns to shareholders of 284% over the past three years. Reported Earnings • May 30
Full year 2021 earnings released: EPS CHF4.15 (vs CHF2.65 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: CHF225.2m (up 29% from FY 2020). Net income: CHF52.3m (up 58% from FY 2020). Profit margin: 23% (up from 19% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year whereas the company’s share price has increased by 37% per year. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improved over the past week After last week's 15% share price gain to CHF194, the stock is trading at a trailing P/E ratio of 62.6x, up from the previous P/E ratio of 54.2x. This compares to an average P/E of 46x in the Chemicals industry in Switzerland. Total returns to shareholders over the past three years are 143%. Valuation Update With 7 Day Price Move • Dec 14
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CHF177, the stock is trading at a trailing P/E ratio of 57.1x, down from the previous P/E ratio of 67.7x. This compares to an average P/E of 44x in the Chemicals industry in Switzerland. Total returns to shareholders over the past three years are 123%. Valuation Update With 7 Day Price Move • Dec 06
Market bids up stock over the past week After last week's 25% share price gain to CHF210, the stock is trading at a trailing P/E ratio of 67.7x, up from the previous P/E ratio of 54.2x. This compares to an average P/E of 43x in the Chemicals industry in Switzerland. Total returns to shareholders over the past three years are 160%. Reported Earnings • Nov 29
First half 2021 earnings released: EPS CHF16.86 The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CHF91.8m (up 18% from 1H 2020). Net income: CHF21.1m (up 37% from 1H 2020). Profit margin: 23% (up from 20% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Nov 11
New 90-day high: CHF1,280 The company is up 37% from its price of CHF935 on 12 August 2020. The Swiss market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period. Is New 90 Day High Low • Oct 22
New 90-day high: CHF1,160 The company is up 30% from its price of CHF895 on 24 July 2020. The Swiss market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period. Valuation Update With 7 Day Price Move • Oct 22
Market bids up stock over the past week After last week's 19% share price gain to CHF1,160, the stock is trading at a trailing P/E ratio of 43.8x, up from the previous P/E ratio of 36.8x. This compares to an average P/E of 42x in the Chemicals industry in Switzerland. Total returns to shareholders over the past three years are 59%. Is New 90 Day High Low • Sep 23
New 90-day high: CHF1,150 The company is up 40% from its price of CHF820 on 25 June 2020. The Swiss market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period.